Copyright: ©Author(s) 2026.
World J Gastrointest Endosc. Apr 16, 2026; 18(4): 118261
Published online Apr 16, 2026. doi: 10.4253/wjge.v18.i4.118261
Published online Apr 16, 2026. doi: 10.4253/wjge.v18.i4.118261
Table 1 Patient characteristics, mean ± SD/median (interquartile range)
| Propofol combination therapy | Propofol monotherapy | P value | |
| Intervention | 2.5 mg midazolame + propofol | Propofol monotherapy | |
| Number of patients | 60 (female 30, male 30) | 60 (female 29, male 31) | |
| Age (years) | 55.5 (50-69) | 57 (50-69) | 0.96 |
| BMI (kg/m2) | 25.4 ± 3.37 | 26 ± 3.03 | 0.33 |
- Citation: Ott C, Dobsch P, Sander M, Schnoy E, Pawlik MT. Moderate sedation with midazolam and propofol is as safe as propofol monotherapy for colonoscopy, but more cost-effective. World J Gastrointest Endosc 2026; 18(4): 118261
- URL: https://www.wjgnet.com/1948-5190/full/v18/i4/118261.htm
- DOI: https://dx.doi.org/10.4253/wjge.v18.i4.118261